Stryker Corporation $SYK Shares Sold by Oak Associates Ltd. OH

Oak Associates Ltd. OH decreased its position in shares of Stryker Corporation (NYSE:SYK) by 30.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,304 shares of the medical technology company’s stock after selling 1,860 shares during the quarter. Oak Associates Ltd. OH’s holdings in Stryker were worth $1,703,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SYK. Consolidated Portfolio Review Corp grew its holdings in Stryker by 4.2% in the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after purchasing an additional 26 shares during the last quarter. Princeton Global Asset Management LLC boosted its position in shares of Stryker by 16.9% in the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after buying an additional 26 shares in the last quarter. Sunflower Bank N.A. grew its stake in Stryker by 4.0% in the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after acquiring an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC increased its holdings in Stryker by 3.2% during the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after acquiring an additional 27 shares in the last quarter. Finally, Sachetta LLC raised its position in Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on SYK shares. Wells Fargo & Company increased their price target on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Royal Bank Of Canada reissued an “outperform” rating and issued a $435.00 price target on shares of Stryker in a report on Friday, November 14th. Barclays increased their price objective on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. Finally, Evercore ISI reduced their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $434.37.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 522,118 shares of company stock valued at $185,381,932 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Stryker Price Performance

SYK stock opened at $370.38 on Tuesday. The company has a market cap of $141.64 billion, a PE ratio of 49.06, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average price of $369.24 and a two-hundred day moving average price of $380.59. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.